Abstracts Archive - Page 518 of 1683 - ATC Abstracts

2020 American Transplant Congress
Proinflammatory Cytokines Including IL-18 Correlate with Cytomegalovirus DNAemia in Solid Organ Transplant Recipients
A. H. Karaba, A. Figueroa, S. C. Ray, R. K. Avery, A. L. Cox
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD
*Purpose: Human cytomegalovirus (CMV) is a common immunomodulatory virus that still causes significant morbidity and mortality in solid organ transplant (SOT) recipients despite prophylaxis. Cytokines…
2020 American Transplant Congress
Extracorporeal Membrane Oxygenation in Pediatric Liver Transplantation
I. A. Ziogas¹, W. R. Johnson¹, C. Thurm², M. Hall², L. K. Matsuoka¹, M. I. Montenovo¹, M. D. Bacchetta¹, J. Godown³, S. P. Alexopoulos¹
¹Vanderbilt University Medical Center, Nashville, TN, ²Children's Hospital Association, Lenexa, KS, ³Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN
*Purpose: Extracorporeal membrane oxygenation (ECMO) can be used for oxygen preservation and hemodynamic support in case of circulatory or respiratory failure. Although the role of…
2020 American Transplant Congress
Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients
L. Al Bizri¹, Z. S. Chaudhry², A. Vahia², J. Williams², J. C. Lemos-Ramirez³, B. Summers⁴, A. Patel⁵, S. Nagai⁶, O. Abreu Lanfranco², M. Ramesh², R. Del Busto², G. Alangaden²
¹Internal Medicine, Henry Ford Health System, Detroit, MI, ²Infectious Disease, Henry Ford Health System, Detroit, MI, ³Department of Transplant Infectious Disease, Memorial Regional Hospital, Hollywood, FL, ⁴Central Pharmacy, Henry Ford Health System, Detroit, MI, ⁵Nephrology, Henry Ford Health System, Detroit, MI, ⁶Surgery Transplant, Henry Ford Health System, Detroit, MI
*Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…
2020 American Transplant Congress
Letermovir for CMV Prophylaxis and Treatment of Resistant/ Refractory CMV Disease in Solid Organ Transplant Recipients
M. Miller¹, S. Scherger², E. Benamu², V. Bajrovic², P. Ramanan², N. Madinger², M. Barron², S. Johnson², T. Campbell², A. Gray³, A. Weinberg⁴, M. Abidi²
¹Clinical Pharmacy, University of Colorado Hospital, Aurora, CO, ²Infectious Diseases, University of Colorado Denver School of Medicine, Aurora, CO, ³Pulmonology, University of Colorado Denver School of Medicine, Aurora, CO, ⁴Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO
*Purpose: Letermovir (LMV) is approved for primary cytomegalovirus (CMV) prophylaxis in hematopoietic cell transplant recipients. Current FDA-approved antiviral options are limited to foscarnet and cidofovir…
2020 American Transplant Congress
Epidemiology of Cytomegalovirus (CMV) in Pediatric Solid Organ Transplant Recipients (SOTR) at Texas Children’s Hospital (TCH)
K. Valencia, K. Hosek, E. Moulton, F. Munoz, G. Demmler-Harrison, C. Bocchini
Baylor College of Medicine, Houston, TX
*Purpose: Despite widespread use of prevention strategies, CMV remains a common opportunistic infection in SOTR. Contemporary data regarding CMV in pediatric SOTR is limited. We…
2020 American Transplant Congress
Solid Organ Transplantation Using Hepatitis C Virus Positive Donor Organs for Hepatitis C Virus Negative Recipients
T. Schiff, R. Bodin, I. Lee, K. Okumura, D. C. Wolf, A. Dhand, A. L. Gass, D. Spielvogel, G. Veillette, S. Nishida, D. Glicklich, K. Wolfe, T. Diflo, H. Sogawa
New York Medical College/ Westchester Medical Center, Valhalla, NY
*Purpose: To determine the effects of transplanting an HCV-positive solid organ to an uninfected patient who is on the transplant waiting list and might otherwise…
2020 American Transplant Congress
Impact and Outcomes of Primary Cytomegalovirus Infection in Seronegative Abdominal Solid Organ Transplant Recipients of Cytomegalovirus Unexposed Donors (D-/R-)
M. Jorgenson¹, M. Hillis¹, N. Friedlander¹, A. Gracon², D. Yang², G. Leverson², J. Smith², R. Redfield²
¹UWHC, Madison, WI, ²UWMF, Madison, WI
*Purpose: Primary cytomegalovirus infection (CMV) in high risk (D+/R-) abdominal solid organ transplant recipients (aSOTRs) is well described, however there is a paucity of literature…
2020 American Transplant Congress
Ehrlichiosis Infection Presenting as Thrombotic Microangiopathy Early after Kidney Transplantation
W. Hassan¹, M. Talwar², V. Balaraman², B. Wall¹, M. Molnar¹
¹Medicine-Nephrology, University of Tennessee Health Science Center, Memphis, TN, ²Department of Surgery, Transplant Surgery, Methodist University Hospital, James D Eason Transplant Institute, Memphis, TN
*Purpose: Fever of unknown origin and clinical picture of Thrombotic MicroAngiopathy (TMA) are diagnostic challenges in the early period after kidney transplantation. Here we present…
2020 American Transplant Congress
Evaluation Of Typical Renal Transplant Infections In Simultaneous Heart-kidney Transplant Recipients
E. J. Henricksen¹, U. Wang¹, R. Lee¹, R. Imai¹, A. Puing², A. Couture², A. Multani³, Y. Moayedi⁴, C. Lenihan⁵, K. K. Khush⁶, J. J. Teuteberg⁵
¹Pharmacy, Stanford Healthcare, Stanford, CA, ²Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, ³Infectious Diseases, UCLA, Los Angeles, CA, ⁴Cardiology, University Health Network, Toronto, ON, Canada, ⁵Department of Medicine, Stanford University, Stanford, CA, ⁶Medicine, Stanford University, Stanford, CA
*Purpose: Simultaneous heart-kidney transplant (SHKT) is an increasingly utilized treatment for patients with end stage heart failure and advanced kidney disease. Data regarding infectious complications…
2020 American Transplant Congress
Phage Therapy for Mycobacterium Abscessus (Mab) Infection after Lung Transplant (LT)
W. Garner¹, R. Dedrick², C. Guerrero², M. Morrell¹, J. D'Cunha³, P. Sanchez¹, G. Hatfull², G. Haidar¹
¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Mayo Clinic Arizona, Phoenix, AZ
*Purpose: LT recipients with Mab infections have poor outcomes. We describe a patient with refractory Mab infection treated with mycobacteriophage therapy.*Methods: A 56-year-old woman with…